(Q45051134)

English

Heterogeneity of response and survival in diffuse histiocytic lymphoma after BACOP therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone).

scientific article published in April 1985

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Heterogeneity of response and survival in diffuse histiocytic lymphoma after BACOP therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone). (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

based on heuristic

inferred from title

large-cell lymphoma

1 reference

based on heuristic

inferred from title

author name string

Levine AM

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Goldstein M

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Meyer PR

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Forman SJ

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Parker JW

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Paganini-Hill A

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Lukes RJ

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Feinstein DI

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 1985

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Hematological Oncology

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

87-98

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Clinical Utility of Lymphocyte Surface Markers Combined with the Lukes-Collins Histologic Classification in Adult Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

21 January 2018

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

21 January 2018

Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

21 January 2018

Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of Haematological Parameters in the Non‐Hodgkin's Malignant Lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in Burkitt's lymphoma importance of total tumor burden

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoblastic sarcoma: morphologic criteria and the distinction of B and T cell types

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-hodgkin's lymphomas.A clinicopathologic study comparing two classifications

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cell lymphomas of large cell type. A variety of malignant lymphomas: "histiocytic" and mixed lymphocytic-"histiocytic"

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant lymphomas of follicular center cell origin in man.III. Prognostic Features

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant lymphoma of peripheral T-lymphocyte origin.Immunologic, pathologic, and clinical features in six patients

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900030203

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HON.2900030203

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45051134&oldid=1638033863"